Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

The Effect of Cognitive Function as Measured by Repeated Cognitive Measures After 12 Weeks Treatment With Donepezil

This study has been completed.
Information provided by:
AstraZeneca Identifier:
First received: December 2, 2009
Last updated: February 6, 2011
Last verified: February 2011
The purpose of this study is to determine if there is improvement or measurable change in cognition after only one month of treatment with donepezil when using a computerized test battery. The results at one month will be compared with the results at 3 months to evaluate this.

Condition Intervention Phase
Alzheimer's Disease
Drug: Donepezil
Drug: Placebo to match Aricept
Early Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator)
Primary Purpose: Basic Science
Official Title: A Randomised, Double-blind, Placebo-controlled, Parallel Design, Multicentre Study in Patients With Mild to Moderate Alzheimer's Disease to Investigate the Effect on Cognitive Function as Measured by Repeated CogState Testing in Relation to Effects on Traditional Cognitive Measures After 12 Weeks

Resource links provided by NLM:

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • CogState Computerized Neurological Test Battery [ Time Frame: Tl. of 25 times: 10 times between Days 3-14, 5 times between Days 36-42, 5 times between Days 64-70, four times between Days 92-97, 1 time on Day 98 ]

Secondary Outcome Measures:
  • Neuropsychological Test Battery (NTB) [ Time Frame: Tl. of 5 times: Once between Days 1-2, Once anytime between Days 3-14, Once anytime between Days 36-42, Once anytime between Days 64-70, Once between Days 92-97 ]
  • Alzheimer Disease Assessment Scale-Cognitive (ADAS-Cog) [ Time Frame: Tl. of 5 times: Once between Days 1-2, Once anytime between Days 3-14, Once anytime between Days 36-42, Once anytime between Days 64-70, Once between Days 92-97 ]
  • Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) [ Time Frame: Tl. of 4 times: Once anytime between Days 3-14, Once anytime between Days 36-42, Once anytime between Days 64-70, Once between Days 92-97 ]

Estimated Enrollment: 155
Study Start Date: December 2009
Study Completion Date: January 2011
Primary Completion Date: January 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
5 mg Donepezil (first 14 days), 10 mg Donepezil (next 70 days)
Drug: Donepezil
5 mg capsule, orally, once daily, first 14 days of treatment
Other Name: Aricept
Drug: Donepezil
10 mg, orally, once daily, for remaining 70 days of treatment
Other Name: Aricept
Placebo Comparator: 2 Drug: Placebo to match Aricept
Placebo capsule, orally, 84 days of treatment


Ages Eligible for Study:   55 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Clinical diagnosis of probable AD according to NINCDS-ADRDA criteria.
  • The patient should live with an appropriate caregiver at home, or in a community dwelling. A caregiver should be capable of accompanying the patient to clinic visits or attending study visits in the patient's home.
  • Patient and caregiver should understand, speak, and read local language.

Exclusion Criteria:

  • Significant neurological disease or dementia other than AD, e.g., mixed dementia, frontotemporal dementia, and Parkinson's Disease.
  • Females of child bearing potential
  • Impaired vision or hearing
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01024660

Canada, Ontario
Research Site
Ottawa, Ontario, Canada
Canada, Quebec
Research Site
Gatineau, Quebec, Canada
Research Site
Montreal, Quebec, Canada
Reearch Site
Quebec, Canada
Research Site
Quebec, Canada
Research Site
Callao, Lima, Peru
Research Site
Callao, Peru
Research Site
Lima, Peru
Research Site
Chojnice, Poland
Research Site
Gdansk, Poland
Research Site
Kalisz, Poland
Research Site
Pila, Poland
Research Site
Poznan, Poland
Research Site
Scinawa, Poland
Research Site
Sopot, Poland
Research Site
Warszawa, Poland
South Africa
Research Site
Cape Town, Western Cape, South Africa
Research Site
Roodepoort, South Africa
Sponsors and Collaborators
Study Director: Malene Jensen Study Delievery Director, AstraZeneca
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: MSD, AstraZeneca Identifier: NCT01024660     History of Changes
Other Study ID Numbers: D2285M00010
Study First Received: December 2, 2009
Last Updated: February 6, 2011

Keywords provided by AstraZeneca:
Patients with Mild to Moderate Alzheimer's Disease

Additional relevant MeSH terms:
Alzheimer Disease
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders
Cholinesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Cholinergic Agents
Neurotransmitter Agents
Physiological Effects of Drugs
Nootropic Agents processed this record on May 23, 2017